Feature | Structural Heart | April 30, 2021

TAVR Access is Inequitable Based Socioeconomics Level and Geography

Structural heart programs for transcatheter aortic valve replacement are less likely to reach underserved communities

The two FDA-clear transcatheter aortic valve replacement (TAVR) valves on the market, the Edwards Lifesciences Sapien 3 (left) and the Medtronic CoreValve (right).

The two FDA-clear transcatheter aortic valve replacement (TAVR) valves on the market, the Edwards Lifesciences Sapien 3 (left) and the Medtronic CoreValve (right).


April 30, 2021 – An analysis of growth patterns in transcatheter aortic valve replacement (TAVR) programs across United States hospitals is being presented as late-breaking clinical science at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Virtual Scientific Sessions. The findings indicate that TAVR structural heart programs are predominately located in metropolitan areas serving patients with higher socioeconomic status, potentially contributing to the disparities in cardiac care.

“TAVR has the potential to be an innovative and effective treatment option for heart valve patients, but can only work to its full potential if all patients have access to it. Our study results show a gap, and as clinicians, we know that these inequities can unfortunately translate into differing outcomes,” said Ashwin Nathan M.D., fellow, cardiovascular medicine, Hospital of the University of Pennsylvania, who presented the study. “While this is just one example of health inequities, our hope is that these findings will activate a change in how we introduce high-tech solutions, so that all communities can access the care they need.”

TAVR is a minimally invasive procedure for patients in need of a valve repair or replacement and is an alternative to surgical aortic valve replacement (SAVR), a treatment option requiring open heart surgery. TAVR also provides eligible patients with quicker procedure times and a shorter recovery. Yet, despite the benefits of novel therapeutics such as TAVR, some patients are still referred to SAVR even if they are ideal candidates – prompting a deeper analysis of how the technology is disseminated in certain populations.

The study involved a cross-sectional analysis of Medicare claims data between Jan. 1, 2012, to Dec. 31, 2018. Linear regression models were used to compare socioeconomic characteristics of patients treated at hospitals that did and did not establish TAVR programs to determine the association between area-level markers of socioeconomic status and TAVR rates.

The findings reveal inequitable access to TAVR programs for non-metropolitan or lower income areas across the country. Between 2012 and 2018, 554 hospitals developed new TAVR programs including 543 (98%) in metropolitan areas, and 293 (52.9%) in metropolitan areas with pre-existing TAVR programs. Compared with hospitals that did not start TAVR programs, hospitals that did start TAVR programs treated patients with higher median household incomes (difference $1,305, 95% CI $134 to $12,477, p=0.03). Furthermore, TAVR rates per 100,000 Medicare beneficiaries were higher in areas with higher median income, despite adjusting for age and clinical comorbidities.

The authors also acknowledge that increasing access to TAVR and structural heart programs will require foresight into how clinical trials and approval for procedures and technologies at hospitals are distributed.

Find out more in the VIDEO: Socioeconomic and Geographic Access to TAVR Programs is Limited — Interview with Ashwin Nathan M.D.

Find more news from the SCAI 2021 virtual meeting

 

Related Structural Heart Content:

Advice For Hospitals Starting a Structural Heart Program

BLOG: Creating a Structural Heart Program is an Investment in the Future of the Hospital

VIDEO: Advice For Hospitals Starting a Structural Heart Program — Interview with John Carroll, M.D.

Interventional Imagers: The Conductors of the Heart Team Orchestra


Related Content

Feature | Cardiovascular Business | By Merilee Kern, MBA

Numerous indicators make clear that the next five years will usher in extreme transformation for a multitude of ...

Home November 09, 2022
Home
News | Cardiovascular Business

November 1, 2022 — Deepak L. Bhatt, MD, MPH, a top expert in cardiovascular medicine and interventional cardiology, has ...

Home November 01, 2022
Home
Feature | Cardiovascular Business

November 1, 2022 — Johnson & Johnson and Abiomed, a world leader in breakthrough heart, lung and kidney support ...

Home November 01, 2022
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the fields of diagnostic and interventional ...

Home November 01, 2022
Home
News | Cardiovascular Business

October 31, 2022 — The Yale School of Medicine announced the passing of Robert W. Berliner Professor Emeritus of ...

Home October 31, 2022
Home
News | Cardiovascular Business

October 24, 2022 — Asher Kimchi, MD, clinical chief of Cardiology, vice-clinical chief of the Department of Medicine ...

Home October 24, 2022
Home
News | Cardiovascular Business

October 20, 2022 — Atlas Healthcare Partners – which specializes in developing and managing ambulatory surgery centers ...

Home October 20, 2022
Home
News | Cardiovascular Business

October 19, 2022 — Mount Sinai Health System’s globally acclaimed cardiologist Valentin Fuster, MD, PhD, has been named ...

Home October 19, 2022
Home
News | Cardiovascular Business

October 12, 2022 — HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG ...

Home October 12, 2022
Home
News | Cardiovascular Business

October 6, 2022 – OpSens Inc., a Quebec-based medical device cardiology-focused company, has announced that it has ...

Home October 06, 2022
Home
Subscribe Now